Date Title Description PDF
26 Jul 2023 On P&L The Company releases the first half 2023 financial results presentation Download
26 Jul 2023 On buy-back programmes The Company reports the commencement, effective as of today, 26 July 2023, of a share buyback program.   Download
10 May 2023 On P&L The Company releases the first quarter 2023 financial results presentation Download
10 May 2023 On P&L The Company releases the press release related to the first quarter 2023 financial results Download
25 Apr 2023 On business and financial situation ROVI commences clinical development of a new three-monthly formulation of Letrozole (Letrozole LEBE) Download

Pages

Date Title Description PDF
15 Feb 2022 On business and financial situation ROVI has announced that the European Commission has authorised the marketing of Okedi® for the treatment of schizophrenia in adults for whom tolerability and effectiveness has been established with oral risperidone. Download
14 Feb 2022 Share buy-back , stabilisation and treasury stock programme Share Buyback Program: transactions conducted between 7 February 2022 and 11 February 2022 Download
07 Feb 2022 Share buy-back , stabilisation and treasury stock programme Share Buyback Program: transactions conducted between 31 January 2022 and 4 February 2022 Download
31 Jan 2022 Share buy-back , stabilisation and treasury stock programme Share Buyback Program: transactions conducted between 24 January 2022 and 28 January 2022 Download
24 Jan 2022 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 17 January 2022 and 21 January 2022 Download

Pages

Date Title Description PDF
29 Apr 2014 Información sobre resultados Download
29 Apr 2014 Convocatorias y Acuerdos de Juntas y Asambleas Generales Download
27 Feb 2014 Información sobre resultados (2) Download
27 Feb 2014 Información sobre resultados Download
27 Feb 2014 Informe anual de gobierno corporativo 2013 Download

Pages